Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by <i>Enterobacteriaceae</i>

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by <i>Enterobacteriaceae</i>

In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for <i>Enterobacteriaceae</i> from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP brea...

Full description

Bibliographic Details
Main Authors: Ga-Eun Park, Jae-Hoon Ko, Sun-Young Cho, Hee-Jae Huh, Jin-Yang Baek, Kwan-Soo Ko, Cheol-In Kang, Doo-Ryeon Chung, Kyong-Ran Peck
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Antibiotics
Subjects:
<i>Enterobacteriaceae</i>
ciprofloxacin
urinary tract infections
Online Access:https://www.mdpi.com/2079-6382/10/4/469

Similar Items

Similar Items